Table 3

Percentage of men in all trials for whom an outcome is reported
Outcome
 Slidenafil n = 7077
 Tadalafil n = 2036
 Vardenafil n = 3274
Efficacy


Improved erections
 83
 83
 100
Mean # erections/week
 20
 0
 0
Successful attempts at SI
 47
 72
 100
More than 60/75% successful
 10
 0
 18
More than 40% successful
 0
 0
 0
Final score IIEF Q3
 94
 27
 26
Mean change IIEF Q3
 91
 27
 26
Final score IIEF Q4
 94
 27
 26
Mean change IIEF Q4
 91
 27
 26
Final score EF Domain
 56
 72
 100
Mean change EF Domain
 54
 83
 77
Normal EF at endpoint
 8
 56
 14
Withdrawals


All-cause
 83
 65
 69
Lack of efficacy
 81
 72
 82
Adverse event
 90
 83
 100
Adverse events


Men with any adverse event
 42
 40
 18
Severe
 27
 25
 35
Serious
 38
 83
 78
Treatment related
 55
 3
 43
Headache
 99
 90
 86
Dyspepsia
 79
 71
 73
Flushing
 99
 73
 73
Nasal congestion/rhinitis
 64
 35
 73
Visual disturbances
 89
 46
 55
Back pain
 13
 73
 9
Myalgia/increased CPK
 16
 60
 18
Flu syndrome
 17
 30
 34
CV events
 24
 27
 33
Limb pain
 10
 11
 0
Fatigue
 3
 15
 0
Priapism
 29
 0
 0
Nausea
 14
 0
 0

Moore et al. BMC Urology 2005 5:18   doi:10.1186/1471-2490-5-18